I. Borget

发表

Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma

M. Schlumberger, D. Hartl, S. Leboulleux, 2013, World Journal of Surgery.

Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital.

E. Baudin, M. Schlumberger, J. Lumbroso, 2012, Thyroid : official journal of the American Thyroid Association.

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

J. Mazières, C. Chouaid, A. Vergnenègre, 2015, BMC Cancer.

Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments.

I. Durand-zaleski, P. Marino, L. Perrier, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.

P. Chanson, E. Baudin, Jacques Young, 2011, The Journal of clinical endocrinology and metabolism.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

J. Soria, F. Bidard, J. Pierga, 2017, European journal of cancer.

Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.

E. Baudin, M. Schlumberger, C. Chougnet, 2010, Endocrine-related cancer.

Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules.

G. de Pouvourville, M. Schlumberger, P. Vielh, 2008, American journal of clinical pathology.

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

G. de Pouvourville, M. Schlumberger, C. Corone, 2007, European journal of endocrinology.

INTRODUCTION OF INNOVATIVE MEDICAL DEVICES AT FRENCH UNIVERSITY HOSPITALS: AN OVERVIEW OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT INITIATIVES

P. Prognon, N. Martelli, H. van den Brink, 2015, International Journal of Technology Assessment in Health Care.

Value of a QALY for France: A New Approach to Propose Acceptable Reference Values.

G. de Pouvourville, B. Detournay, S. Roze, 2020, Value in Health.

HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT FOR THE ADOPTION OF INNOVATIVE MEDICAL DEVICES WITHIN FRENCH HOSPITALS: OPPORTUNITIES AND CHALLENGES FOR INDUSTRY

G. Mercier, N. Martelli, I. Borget, 2017, International Journal of Technology Assessment in Health Care.

Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

J. Pignon, M. Ducreux, O. Bouché, 2007, Oncology.

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.

S. Culine, G. Gravis, F. Joly, 2021, European urology.

Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.

M. Schlumberger, O. Morel, S. Bardet, 2018, The lancet. Diabetes & endocrinology.

Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer.

F. Bidault, E. Baudin, S. Ippolito, 2016, The Journal of clinical endocrinology and metabolism.

Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial.

M. Schlumberger, J. Bonastre, O. Morel, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

M. Schlumberger, O. Morel, S. Bardet, 2012, The New England journal of medicine.

Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.

F. Bidault, E. Baudin, M. Schlumberger, 2012, Thyroid : official journal of the American Thyroid Association.

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates

B. Godman, M. Schlander, J. Espín, 2018, Applied Health Economics and Health Policy.

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)

F. Matonti, I. Borget, P. Gascon, 2021, European journal of ophthalmology.

The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review.

S. Bardet, S. Zerdoud, S. Leboulleux, 2019, Bulletin du cancer.

Evaluation of the accuracy of a computer-aided diagnosis (CAD) system in breast ultrasound according to the radiologist's experience.

Isabelle Borget, Corinne Balleyguier, Clarisse Dromain, 2012, Academic radiology.

Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy.

T. de Baère, M. Ducreux, E. Baudin, 2013, Endocrine-related cancer.

F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients

BorgetIsabelle, E. Baudin, M. Schlumberger, 2019, Thyroid.

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

E. Letouzé, E. Baudin, Jacques Young, 2014, International journal of cancer.

One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.

A. Tabarin, E. Baudin, Jacques Young, 2013, The Journal of clinical endocrinology and metabolism.

Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database

J. L. Lacau St Guily, I. Borget, V. Rémy, 2010, Head & neck oncology.

Treatment of lung cancer: will financial issues become a criterion of choice?

C. Chouaid, A. Vergnenègre, I. Borget, 2013, Expert review of pharmacoeconomics & outcomes research.

Global thyroid estimates in 2020.

M. Schlumberger, S. Leboulleux, I. Borget, 2022, The lancet. Diabetes & endocrinology.

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.

F. Bidault, E. Baudin, M. Schlumberger, 2017, The Journal of clinical endocrinology and metabolism.

Prophylactic Level II Neck Dissection Guided by Frozen Section for Clinically Node-Negative Papillary Thyroid Carcinoma: Is It Useful?

M. Schlumberger, D. Hartl, S. Leboulleux, 2014, World Journal of Surgery.

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

C. Chouaid, C. Audigier-Valette, A. Vergnenègre, 2017, Journal of thoracic disease.

Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.

Xiao-Jun Ma, Yuling Luo, J. Scoazec, 2016, Oral oncology.

Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen

M. Schlumberger, M. Ricard, I. Borget, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients

M. Schlumberger, S. Leboulleux, C. Bournaud, 2008, Journal of Nuclear Medicine.

131 I Effective Half-Life and Dosimetry in Thyroid Cancer Patients

M. Schlumberger, S. Leboulleux, C. Bournaud, 2008 .

Calcitonin Determination in Patients with Nodular Thyroid Disease

G. de Pouvourville, M. Schlumberger, I. Borget, 2007 .

Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.

V. Baracos, S. Broutin, A. Paci, 2013, The Journal of clinical endocrinology and metabolism.

Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians.

P. Prognon, N. Martelli, J. Pineau, 2016, Australian health review : a publication of the Australian Hospital Association.

Robot-Assisted Surgery vs Robotic Stereotactic Body Radiotherapy in Prostate Cancer: A Cost-Utility Analysis

Cyrus Chargari, M. Zerbib, N. Martelli, 2022, Frontiers in Oncology.

Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals.

G. Scotland, J. Luyten, M. Connolly, 2022, Best practice & research. Clinical obstetrics & gynaecology.

The learning curve in transcatheter aortic valve implantation clinical studies: A systematic review

P. Prognon, N. Martelli, Sarah Fontenay, 2020, International Journal of Technology Assessment in Health Care.

High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.

P. Chanson, A. Tabarin, A. Paci, 2012, European journal of endocrinology.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.

A. Tabarin, E. Baudin, F. Beuschlein, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Partial versus whole breast irradiation: Side effects, patient satisfaction and costs.

C. Bourgier, I. Borget, S. Rivera, 2019, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients?: Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745)

M. Schlumberger, C. Chougnet, O. Morel, 2021, Journal of the Endocrine Society.

A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies.

T. Friede, J. Karnon, Stephen Palmer, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Impact of COVID-19 on healthcare organisation and cancer outcomes

D. Planchard, M. Ducreux, S. Michiels, 2021, European Journal of Cancer.

mitotane measurement during the first three months of follow-up

P. Chanson, A. Paci, E. Baudin, 2011 .

Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?

P. Chanson, E. Baudin, Jacques Young, 2011, Hormones & cancer.

Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France

F. Cotté, A. Gaudin, V. Grumberg, 2022, Journal of medical economics.

Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients

T. de Baère, E. Baudin, M. Schlumberger, 2017, Hormones and Cancer.

Anatomic Variability of the Upper Mediastinal Lymph Node Level VII

M. Schlumberger, D. Hartl, S. Leboulleux, 2016, World Journal of Surgery.

The Cost of Thromboembolic Events in Hospitalized Patients with Breast or Prostate Cancer in France

F. Scotté, N. Martelli, I. Borget, 2015, Advances in Therapy.

New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues.

N. Martelli, H. van den Brink, I. Borget, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

A. Vergnenègre, I. Borget, C. Chouaïd, 2014, ClinicoEconomics and outcomes research : CEOR.

levels are correlated with the progression-free survival in medullary

E. Baudin, M. Schlumberger, C. Chougnet, 2012 .

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

J. Soria, C. Massard, M. Le Deley, 2012, European journal of cancer.

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

S. Michiels, C. Lebbé, B. Dréno, 2018, European journal of cancer.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

B. Chauffert, M. Schlumberger, V. Rohmer, 2015, Thyroid : official journal of the American Thyroid Association.

Expected Impact of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) on Health Technology Assessment

P. Auquier, M. Toumi, C. Chouaid, 2016 .

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.

M. Schlumberger, C. Chougnet, Thierry Nguyen, 2017, Thyroid : official journal of the American Thyroid Association.

Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.

S. de Botton, B. Wyplosz, E. Chachaty, 2014, Medecine et maladies infectieuses.

Value of cardiophrenic angle lymph node for the diagnosis of colorectal peritoneal carcinomatosis.

M. Ducreux, D. Elias, C. Dromain, 2013, European journal of cancer.

Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers.

M. Ducreux, D. Elias, C. Dromain, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up

F. Bidault, E. Baudin, M. Schlumberger, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting

Isabelle Borget, Nicolas Martelli, Paul Hansen, 2016, J. Biomed. Informatics.

Frequency and intensity of pain related to thyroid nodule fine-needle aspiration cytology.

E. Baudin, S. Dauchy, M. Schlumberger, 2013, Thyroid : official journal of the American Thyroid Association.

Recombinant Human Thyroid-Stimulating Hormone: Use in Papillary and Follicular Thyroid Cancer

G. de Pouvourville, M. Schlumberger, F. Pacini, 2007, Hormone Research in Paediatrics.

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

M. Schlumberger, L. Vija, S. Zerdoud, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

B. Chauffert, S. Culine, R. Janssen, 2019, Annals of Oncology.

Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?

C. Chouaid, A. Vergnenègre, I. Borget, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

802PPatient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial

S. Culine, G. Gravis, P. Barthélémy, 2017 .

Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

S. Culine, G. Gravis, F. Joly, 2019, Journal of Clinical Oncology.

A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty

P. Prognon, N. Martelli, H. van den Brink, 2015, PloS one.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

D. Planchard, J. Soria, C. Lindsay, 2017, Cancer research.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

D. Planchard, F. André, J. Adam, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locally unresectable differentiated thyroid cancer: outcomes and perspectives

E. Baudin, M. Schlumberger, D. Hartl, 2020, Endocrine.

Thyroidectomy without Radioiodine in Low-Risk Thyroid Cancer. Reply.

M. Schlumberger, S. Leboulleux, I. Borget, 2022, The New England journal of medicine.

Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.

M. Schlumberger, C. Chougnet, S. Bardet, 2022, The New England journal of medicine.

Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.

E. Baudin, M. Schlumberger, C. Chougnet, 2013, European journal of endocrinology.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

J. Pignon, C. Chouaid, E. Quoix, 2011, European Respiratory Journal.

Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.

A. Tabarin, E. Baudin, F. Beuschlein, 2019, The Journal of clinical endocrinology and metabolism.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

D. Planchard, E. Baudin, M. Schlumberger, 2015, Endocrine-related cancer.

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France

S. Michiels, J. Grob, C. Lebbé, 2022, Current oncology.

Quality‐of‐life assessment in French patients with metastatic melanoma in real life

S. Michiels, J. Grob, C. Lebbé, 2020, Cancer.

Management and treatment outcomes of tuberculous patients, eastern Paris, France, 2004.

G. Hejblum, C. Chouaid, H. Mallet, 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting

E. Solary, N. Droin, J. Bonastre, 2021, The European Journal of Health Economics.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Patricia Marino, Rajae Touzani, Lionel Perrier, 2018, European Journal of Human Genetics.

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Dede Sika Kossi, On behalf of NGSEco Group, I. Durand-zaleski, 2017, European Journal of Human Genetics.

Advantages and disadvantages of 3-dimensional printing in surgery: A systematic review.

Isabelle Borget, Nicolas Martelli, Judith Pineau, 2016, Surgery.

Imaging: towards a global solution to overcome the cancer pandemic.

C. Balleyguier, N. Lassau, F. Barlesi, 2021, The Lancet. Oncology.

MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)

M. Schlumberger, S. Bardet, A. Schiazza, 2021, Journal of the Endocrine Society.

Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy.

Isabelle Borget, Stefan Michiels, Philippe Bourget, 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer

E. Baudin, M. Schlumberger, S. Leboulleux, 2020, Endocrine.

[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].

F. Scotté, C. Chouaid, G. Freyer, 2016, Bulletin du Cancer.

Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004

G. Hejblum, C. Chouaid, H. Mallet, 2010, BMC public health.

Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer

E. Lanoy, S. Antoun, I. Borget, 2013, Current opinion in supportive and palliative care.

Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.

M. Schlumberger, F. Borson‐Chazot, O. Mundler, 2011, The Journal of clinical endocrinology and metabolism.

Existing reporting guidelines for clinical trials are not completely relevant for implantable medical devices: a systematic review.

Isabelle Borget, Jean-Marc Alsac, Nicolas Martelli, 2017, Journal of clinical epidemiology.

Safety and quality assurance of chemotherapeutic preparations in a hospital production unit: Acceptance sampling plan and economic impact

A. Paci, P. Bourget, L. Mercier, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic.

M. Mathieu, F. André, C. Balleyguier, 2016, European journal of cancer.

Economic burden of HPV-related cancers in France.

P. Mathevet, L. Abramowitz, I. Borget, 2011, Vaccine.

Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis.

C. Chouaid, P. Tilleul, I. Borget, 2005, Lung cancer.

Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.

E. Baudin, M. Schlumberger, C. Chougnet, 2012, European journal of endocrinology.

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

D. Planchard, J. Soria, C. Lindsay, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of meta-analyses and of large randomized trials in the study of cancer treatments.

J. Pignon, C. Hill, A. Aupérin, 2009, Lung cancer.

A multicenter prospective observational study of the conformity of temozolomide prescriptions in France

F. Pinguet, S. Taillibert, O. Chinot, 2012, Pharmacoepidemiology and drug safety.

Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review

N. Martelli, I. Borget, L. Farah, 2023, Artif. Intell. Medicine.

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends

M. Toumi, C. Chouaid, I. Borget, 2016, Targeted Oncology.

Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.

E. Baudin, F. Pattou, Jacques Young, 2013, The Journal of clinical endocrinology and metabolism.

Loco‐regional Control After Neo‐adjuvant Chemotherapy and Conservative Treatment for Locally Advanced Breast Cancer Patients

C. Balleyguier, P. Vielh, C. Bourgier, 2014, The breast journal.

S0266462320000100jra 152..161

P. Prognon, N. Martelli, Sarah Fontenay, 2020 .

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

G. Zalcman, P. Fournel, D. Pérol, 2012, BMC Cancer.

HARMONIZING HEALTH TECHNOLOGY ASSESSMENT PRACTICES IN UNIVERSITY HOSPITALS: TO WHAT EXTENT IS THE MINI-HTA MODEL SUITABLE IN THE FRENCH CONTEXT?

P. Prognon, N. Martelli, H. van den Brink, 2017, International Journal of Technology Assessment in Health Care.

M. Schlumberger, I. Borget, G. Pouvourville, 2007, Nature Clinical Practice Endocrinology &Metabolism.

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.

A. Hollebecque, L. Verlingue, C. Massard, 2019, JCO clinical cancer informatics.

Single‐use flexible bronchoscopes compared with reusable bronchoscopes: Positive organizational impact but a costly solution

Isabelle Borget, Nicolas Martelli, Judith Pineau, 2018, Journal of evaluation in clinical practice.

[Comprehensive geriatric assessment and complications after resection for lung cancer].

C. Chouaid, I. Borget, C. Raynaud, 2010, Revue des maladies respiratoires.

A Prospective Study on 715 Patients Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer:

M. Schlumberger, F. Borson‐Chazot, O. Mundler, 2011 .

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

A. Tabarin, E. Baudin, F. Pattou, 2011 .

Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.

E. Baudin, M. Schlumberger, C. Chougnet, 2014, European journal of endocrinology.

Prognostic factors of advanced unresectable by stage III and IV ENS@T adrenocortical carcinomas (ACC)

A. Tabarin, E. Baudin, J. Bertherat, 2013 .

Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy

F. Slimano, B. Besse, I. Borget, 2018, International Journal of Clinical Pharmacy.

Follow-up of differentiated thyroid cancer – what should (and what should not) be done

S. Filetti, M. Schlumberger, G. Grani, 2018, Nature Reviews Endocrinology.

Assessment of Performance, Interpretability, and Explainability in Artificial Intelligence–Based Health Technologies: What Healthcare Stakeholders Need to Know

S. Katsahian, A. Guilloux, N. Martelli, 2023, Mayo Clinic Proceedings: Digital Health.

Cost Of Genome Analysis: The Sanger Sequencing Method.

J. Merlio, P. Marino, L. Lacroix, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Prognostic of recurrence and survival in poorly differentiated thyroid cancer.

M. Nikiforova, Y. Nikiforov, E. Baudin, 2022, Endocrine-Related Cancer.

1743MO MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation

M. Schlumberger, D. Benisvy, S. Leboulleux, 2021, Annals of Oncology.

Changes in the quality of life of advanced melanoma patients after 12 weeks of treatment with ipilimumab compared to gp100 in a phase III clinical trial.

C. Lebbé, A. Gaudin, B. Bregman, 2013 .

Projecting overall survival in health-economic models: uncertainty and maturity of data

S. Roze, L. Eberst, I. Borget, 2023, Current medical research and opinion.

Post-operative radioactive iodine administration in patients with low-risk thyroid cancer

M. Schlumberger, S. Leboulleux, I. Borget, 2022, Nature Reviews Endocrinology.

Radioactive iodine ablation in low-risk thyroid cancer - Authors' reply.

M. Schlumberger, S. Leboulleux, I. Borget, 2018, The lancet. Diabetes & endocrinology.

Comparison of four strategies of radioiodine ablation in patients with thyroid cancer with low-risk of recurrence: the randomized, prospective ESTIMABL study

M. Schlumberger, S. Bardet, B. Catargi, 2011 .

[A prospective study of quality of life and treatment of chemotherapy-induced anaemia in lung cancer].

C. Chouaid, P. Tilleul, I. Borget, 2007, Revue des maladies respiratoires.

Treatment and follow-up of low-risk patients with thyroid cancer

M. Schlumberger, S. Leboulleux, I. Borget, 2011, Nature Reviews Endocrinology.

The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer

Eric Baudin, Isabelle Borget, Marcel Ricard, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

O-113 Effectiveness and treatment cost of assisted reproduction technology for women stimulated by gonadotropin in France: A cohort study using the National Health Database

M. Grynberg, I. Cédrin-Durnerin, I. Borget, 2021, Human Reproduction.

I. Borget, T. Grivel, 2010, Bulletin du Cancer.

Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?

C. Balleyguier, S. Delaloge, C. Mazouni, 2017, European journal of cancer.

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial

J. Pignon, M. Ducreux, C. Lepage, 2019, Expert review of pharmacoeconomics & outcomes research.

Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.

C. Chougnet, S. Zerdoud, A. Al Ghuzlan, 2023, Thyroid : official journal of the American Thyroid Association.

ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

M. Schlumberger, S. Bardet, L. Brunaud, 2023, Trials.

Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review

M. Hamoir, C. Silver, A. Shaha, 2015, European Archives of Oto-Rhino-Laryngology.

Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

M. Schlumberger, S. Bardet, L. Brunaud, 2023, Trials.

F-18-Dopa PET/CT is more sensitive than whole body MRI for the localization of persistent/recurrent disease of medullary thyroid cancer patients.

E. Baudin, M. Schlumberger, C. Dromain, 2019, Thyroid.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Dede Sika Kossi, On behalf of NGSEco Group, I. Durand-zaleski, 2018, European Journal of Human Genetics.

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents

C. Chouaid, A. Vergnenègre, I. Borget, 2013, ClinicoEconomics and outcomes research : CEOR.